Tablet containing Melsartan potassium and preparation method thereof
Through the step-by-step process of gas flow crushing and fluidized bed granulation and wet granulation with hydrophilic auxiliary materials, the problems of insoluble and hydrolyzable measartan potassium are solved, the dissolution behavior and granulation efficiency are improved, and the production cost is reduced. The efficient preparation of measartan potassium tablets was achieved.
Patent Information
- Application Number
- CN202410654475.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-03
AI Technical Summary
Measartan potassium and azisartan are difficult to soluble drugs. The conventional micronization process increases the specific surface area but increases hydrophobicity, resulting in poor dissolution behavior and is prone to hydrolysis under high temperature and high humidity conditions, resulting in complex and high cost of granulation.
Use airflow crushing with hydrophilic auxiliary materials to make the raw materials more hydrophilic, and through the step-by-step process of fluidized bed granulation and wet granulation, reduce the amount of fluidized bed granulation liquid, shorten the granulation time, and use mannol Fillers and disintegrants can improve the fluidity and disintegration performance of materials and improve dissolution behavior.
The dissolution platform of Measartan potassium tablets is improved, the granulation time is shortened, the production cost is reduced, the product quality is consistent with the reference preparation, and the prepared particles have good fluidity and compressibility.
Smart Images

Figure CN119055601A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine preparation, and relates to a tablet containing asartan potassium and a preparation method thereof. Background Art
[0002] Azilsartan Potassium is a prodrug that can be quickly converted into the active ingredient Azilsartan after oral absorption. The latter can block the action of angiotensin II by selectively blocking the binding of angiotensin II to AT1 receptors in various tissues, thereby achieving the effect of lowering blood pressure. Angiotensin II is the main pressor substance of RAAS, which has the effects of constricting blood vessels, stimulating the synthesis and release of aldosterone, exciting the heart, and reabsorb sodium by the kidneys. Azilsartan Potassium can not only control blood pressure well, but also reduce the risk of cardiovascular diseases and diabetes.
[0003] Both Azilsartan Potassium and Azilsartan are poorly soluble drugs, and their solubility is relatively low, so when being prepared as oral preparations, it is necessary to have a good dissolution curve to be well absorbed by the gastrointestinal tract, otherwise, its absorption and biological benefit will be greatly hindered. Conventional micronization process also increases its hydrophobicity while improving specific surface area, so there is no obvious improvement in dissolution behavior. In addition, Azilsartan Potassium is an ester salt, which is easily hydrolyzed to Azilsartan under high temperature and high humidity conditions. Therefore, it is necessary to strictly control temperature and humidity during granulation, which will inevitably lead to extended granulation time and increase production costs.
[0004] Therefore, there is an urgent need for a preparation process for Asartan Potassium Tablets that can both ensure that product quality meets requirements and reduce production costs as much as possible. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides a tablet containing mesartan potassium and a preparation method thereof: ① by air flow pulverization with hydrophilic auxiliary materials, the raw material drug and mannitol are fully mixed while reducing the particle size, and the hydrophilicity is improved, so that it can be dissolved better. ② adopting fluidized bed granulation and wet granulation step-by-step granulation process: the liquid dosage of the fluidized bed granulation part can be reduced, and the granulation time can be shortened while ensuring the stability of the raw material drug during the granulation process; wet granulation of part of the filler and disintegrant can not only improve the fluidity and compressibility of the material, but also significantly enhance the disintegration performance of the material, and well improve the dissolution behavior of mesartan potassium tablets.
[0006] The technical solution provided by the present invention is as follows: A tablet containing lasartan potassium is prepared from the following components in parts by mass: 85-86 parts of lasartan potassium, 220-240 parts of a filler, 2-8 parts of a pH adjuster, 8-12 parts of a binder, 26-29 parts of a disintegrant, and 3-4 parts of a lubricant.
[0007] Furthermore, the filler is one or more of mannitol, lactose, and microcrystalline cellulose; the pH adjuster is one or more of fumaric acid, citric acid, and sodium citrate; the binder is one or more of hydroxypropyl cellulose, hydroxypropyl methylcellulose, and hydroxyethyl cellulose; the disintegrant is one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, and sodium starch glycolate; and the lubricant is one or more of magnesium stearate, stearic acid, and sodium stearyl fumarate.
[0008] The present invention also provides a method for preparing the above-mentioned tablet containing asartan potassium, comprising the following steps: Add a pH adjuster to water and stir to dissolve completely, then stir and add a portion of the prescribed amount of binder until it is completely dissolved to obtain a first binder solution; co-process mesartan potassium and a filler in a jet mill, add the mixture to a fluidized bed granulator, add the first binder solution by atomizing spray, perform fluidized bed granulation and drying, and obtain fluidized bed granulation particles after dry granulation; Add the remaining amount of binder in the prescription into the water while stirring until it is completely dissolved to obtain a second binder solution; place the filler and the disintegrant in a wet mixing granulator for premixing, increase the cutting speed after the premixing is complete, pump the second binder solution into the wet mixing granulator for granulation, and perform wet granulation, and perform dry granulation after drying to obtain wet granulated granules; The fluidized bed granulation granules, the wet granulation granules and the lubricant are mixed to obtain an intermediate, and the intermediate is tableted to obtain a tablet containing mesartan potassium.
[0009] Furthermore, the ratio of the adhesives used in the first adhesive solution and the second adhesive solution is 3:1-2.
[0010] Furthermore, mesartan potassium and fillers are added into a fluidized bed granulator, the inlet air temperature is 55-65°C, the material temperature is 25-35°C, and the air volume is 40-70 m³ / h.
[0011] Furthermore, the first binder solution is added by atomizing spray, and the peristaltic pump adding speed is controlled to be 30-50 rpm and the atomizing pressure is 3-5 bar, and fluidized bed granulation and drying are performed.
[0012] Furthermore, the dry granulation step includes: passing the dried granules through a 1.0±0.1 mm aperture sieve, and controlling the granulation machine frequency to 30±2 Hz for granulation.
[0013] Furthermore, the method of placing the filler and disintegrant in a wet mixing granulator for premixing, increasing the cutting speed after the premixing is complete, and pumping the second binder solution into the wet mixing granulator for granulation comprises: placing the filler and disintegrant in a wet mixing granulator for premixing, the premixing stirring speed is 200±10rpm, the cutting speed is 1000±100rpm, and the mixing time is 10±2min; setting the stirring speed to 200rpm, the cutting speed to 1500rpm, and pumping the second binder solution into the wet mixing granulator for granulation.
[0014] Furthermore, the mixing frequency of the total mixing is 20±2 Hz, and the mixing time is 10±2 min.
[0015] Furthermore, the drying of the intermediate tablets is specifically: drying the intermediate in a reduced pressure drying oven at 40±2° C. for 16±2 h. Beneficial Effects
[0016] The preparation method of the tablet containing mesartan potassium of the present invention improves the dissolution platform to be consistent with the reference preparation through the process of co-crushing raw materials and auxiliary materials; at the same time, a fluidized bed granulation and wet granulation step-by-step granulation process is adopted, and the temperature and humidity in the fluidized bed granulation process are strictly controlled, so as to reduce the granulation time and production cost while ensuring the stability of the raw materials; the particles prepared by the process have good fluidity and compressibility, and have good disintegration performance, greatly improve the dissolution behavior of the preparation, and can stably prepare products with the same quality as the reference preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 These are the dissolution curves of the reference preparation and the homemade preparation in pH 4.5+0.5% SDS medium. DETAILED DESCRIPTION
[0018] A tablet containing lasartan potassium is prepared from the following components in parts by mass: 85-86 parts of lasartan potassium, 220-240 parts of a filler, 2-8 parts of a pH adjuster, 8-12 parts of a binder, 26-29 parts of a disintegrant, and 3-4 parts of a lubricant.
[0019] Among them, the filler is one or more of mannitol, lactose, and microcrystalline cellulose; the pH adjuster is one or more of fumaric acid, citric acid, and sodium citrate; the binder is one or more of hydroxypropyl cellulose, hydroxypropyl methylcellulose, and hydroxyethyl cellulose; the disintegrant is one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, and sodium starch glycolate; the lubricant is one or more of magnesium stearate, stearic acid, and sodium stearyl fumarate.
[0020] The method for preparing the tablet containing Asartan potassium comprises the following steps: 1. Premix the API and filler and air flow pulverize them, with the pulverizing pressure being 0.1~0.3MPa. The setting of 0.1~0.3MPa pulverizing pressure can reduce the adsorption and agglomeration of the raw materials and fully mix the API and soluble excipients.
[0021] 2. Prepare an aqueous solution of the adhesive and the pH adjuster for later use; 3. Preparation of granules by fluidized bed granulation and wet granulation step-by-step granulation process; 1) Fluidized bed granulation (drug-containing granules) parameters are as follows: The peristaltic pump liquid addition speed is 30~50rpm, Atomization pressure 3~5bar, Material temperature 25~35℃; By controlling the fluidized bed parameters, the peristaltic pump adds liquid at a higher speed, and the atomization pressure maintains a higher pressure state, so that the instantaneous humidity in the chamber increases, achieving: ① Eliminate the electrostatic adsorption of raw materials to avoid the loss of raw materials; ② The particles can be formed quickly and are not easy to break, which improves the fluidity and compressibility of the material; ③ Enhance the anti-adhesion property of particles and solve the sticking problem of tableting; ④Improve the dissolution behavior of the preparation and significantly enhance its similarity with the original preparation.
[0022] 2) Wet granulation (without drug particles): Stirring speed 200rpm, cutting speed 1500rpm, Wet granulation can make the material have good fluidity and bulk density, thereby improving the compressibility of the material; at the same time, it has good disintegration performance, thereby improving the dissolution behavior of the preparation and increasing the similarity with the original preparation.
[0023] Fluidized bed granulation process introduction: Fluidized bed multifunctional drying granulator is a new type of pharmaceutical equipment developed on the basis of boiling drying technology. It integrates granulation and drying functions and is widely used in the pharmaceutical industry. Fluidized bed multifunctional drying granulator is mainly composed of the host, air handling system, spray system, main air duct system, exhaust system, electric control cabinet, etc.
[0024] Working principle of fluidized bed multifunctional drying granulator: The airflow is sucked by the negative pressure of the induced draft fan, passes through the air filter, heat exchanger, and air supply duct from the air flow distribution plate into the fluidized bed granulation chamber, and the powder is agitated and boiled into a fluidized state. The atomized liquid material and compressed air enter the nozzle through their respective pipelines, atomized into fine droplets, sprayed in the fluidized bed granulation chamber, mixed with the powder, and bonded into particles. At the same time, the particles are dried by hot air, and a part of the fine powder rises to the filter bag and is captured. After a certain period of time, the left exhaust valve is closed, and the filter bag in the left chamber shakes up and down under the action of the cylinder, and the powder that is shaken off falls back into the fluidized bed for granulation again. After shaking the bag, the left exhaust valve is opened again, and after a certain period of time, the right exhaust valve is closed, and the filter bag in the right chamber of the filter chamber shakes. The left and right chambers shake alternately in this cycle to clean the captured powder, keep the filter bag unobstructed, and finally complete the drying and granulation operations. Example 1
[0025] Wet granulation process
[0026] The preparation method comprises: ① Weighing: Accurately weigh the raw and auxiliary materials in the prescription and set aside; ② Preparation of granulation liquid: accurately weigh the prescribed amount of purified water in a beaker, add the prescribed amount of fumaric acid while stirring until completely dissolved, then add sodium citrate and dissolve completely, finally stir and add the prescribed amount of binder until completely dissolved, and set aside; ③ Premixing: Place the active ingredient mesartan potassium, filler mannitol and microcrystalline cellulose in a wet mixing granulator, set the stirring speed to 200 rpm, the cutting speed to 1000 rpm, and mix for 10 minutes; ④ Wet granulation: Set the stirring speed to 200rpm and the cutting speed to 1500rpm, pump the granulation liquid into the wet mixing granulator for granulation, control the wetting agent to be added within 5min, and stop the machine to discharge the material; ⑤ Wet granulation: soft materials pass through a 6*6mm aperture screen and the granulation machine frequency is controlled at 30Hz for granulation; ⑥ Drying: Set the inlet air temperature to 50~60℃, the material temperature to 30~40℃, and the air volume to 40~60m³ / h to dry the material. After drying for 10 minutes, take samples to control the moisture content. If the moisture content is less than 2.0%, stop drying and discharge the material. ⑦ Dry granulation: the granules are passed through a 1.0 mm sieve, the granulation machine frequency is controlled to 30 Hz, and the granules are weighed; ⑧ Total mixing: convert the amount of disintegrant cross-linked carboxymethyl cellulose sodium and lubricant magnesium stearate, add them and the dry granules prepared in ⑦ into a mixer, set the mixing frequency to 20 Hz, mix for 10 minutes, and obtain the intermediate; ⑨ Tableting: Calculate the standard tablet weight according to the intermediate content, control the tablet weight difference by ±3% and perform tableting to obtain plain tablets; ⑩ Drying: Dry the plain tablets in a vacuum drying oven at 40°C for 16 hours. Example 2
[0027] Fluidized bed granulation process The prescription composition is the same as that of Example 1.
[0028] The preparation method comprises: ① Weighing: Accurately weigh the raw and auxiliary materials in the prescription and set aside; ② Preparation of granulation liquid: accurately weigh the prescribed amount of purified water in a beaker, add the prescribed amount of fumaric acid while stirring until completely dissolved, then add sodium citrate and dissolve completely, finally stir and add the prescribed amount of binder until completely dissolved, and set aside; ③ Add the prescribed amount of active ingredient mesartan potassium, filler mannitol and microcrystalline cellulose into the fluidized bed granulator, set the inlet air temperature to 55-65°C, the material temperature to 25-35°C, the air volume to 40-70m³ / h, add the binder by atomization spraying, control the peristaltic pump liquid addition speed to 30-50rpm, the atomization pressure to 3-5bar, perform fluidized bed granulation and drying, and start sampling for moisture control 5 minutes after the binder spraying is completed. Stop drying and discharge when the moisture content is <2.0%; ④ Dry granulation: the granules are passed through a 1.0 mm sieve, the granulation machine frequency is controlled to 30 Hz, and the granules are weighed; ⑤ Total mixing: convert the amount of disintegrant cross-linked carboxymethyl cellulose sodium and lubricant magnesium stearate, add them and the dry granules prepared in step ④ into a mixer, set the mixing frequency to 20 Hz, mix for 10 minutes, and obtain the intermediate; ⑥ Tableting: Calculate the standard tablet weight according to the intermediate content, control the tablet weight difference of ±3% for tableting, and obtain plain tablets; ⑦ Drying: Dry the plain tablets in a vacuum drying oven at 40°C for 16 hours. Example 3
[0029] Fluidized bed granulation and wet granulation step by step granulation process The prescription composition is the same as that of Example 1.
[0030] The preparation method comprises: 1) Fluidized bed granulation (drug-containing granules) ① Weighing: Accurately weigh the prescription amount of each auxiliary material and the raw material that has been pulverized by the airflow, and set aside; ② Preparation of adhesive: accurately weigh 3 / 4 of the prescription amount of purified water in a beaker, add the prescription amount of fumaric acid while stirring until completely dissolved, then add sodium citrate and dissolve completely, and finally stir and add 3 / 4 of the prescription amount of adhesive until completely dissolved to obtain a first adhesive solution; ③ Add the active ingredient mesartan potassium and the filler mannitol into the fluidized bed granulator, set the inlet air temperature to 55-65°C, the material temperature to 25-35°C, the air volume to 40-70m³ / h, add the first binder solution by atomization spraying, control the peristaltic pump liquid addition speed to 30-50rpm, the atomization pressure to 3-5bar, perform fluidized bed granulation and drying, wait for the first binder solution to be sprayed, start sampling and control moisture content after 5 minutes, stop drying when the moisture content is <2%, and discharge the material; ④ Dry granulation: The granules are passed through a 1.0 mm pore size sieve, and the granulation frequency of the granulator is controlled to be 30 Hz. The granules are weighed to obtain fluidized bed granulation granules (drug-containing granules); 2) Wet granulation (without drug particles) ① Preparation of adhesive: accurately weigh 1 / 4 of the prescribed amount of purified water in a beaker, add 1 / 4 of the prescribed amount of adhesive while stirring until completely dissolved, to obtain a second adhesive solution; ② Premixing: Place the filler microcrystalline cellulose and the disintegrant cross-linked carboxymethyl cellulose sodium in a wet mixing granulator, set the stirring speed to 200 rpm and the cutting speed to 1000 rpm, and mix for 10 minutes; ③ Wet granulation: set the stirring speed to 200 rpm and the cutting speed to 1500 rpm, pump the second binder solution into the wet mixing granulator for granulation, control the binder to be added within 5 minutes, and stop the machine to discharge the material; ④ Wet granulation: soft materials pass through a 6*6mm aperture screen and the granulation machine frequency is controlled at 30Hz for granulation; ⑤ Drying: Set the inlet air temperature to 50~60℃, the material temperature to 30~40℃, and the air volume to 40~60m³ / h to dry the material. After drying for 10 minutes, take a sample to control the moisture content. If the moisture content is <2.0%, stop drying and discharge the material. ⑥ Dry granulation: The granules are passed through a 1.0 mm pore size sieve, and the granulation frequency of the granulator is controlled to 30 Hz for granulation, and then weighed to obtain wet granulation granules (without drug particles); 3) Total mixing: Add the fluidized bed granulation granules (drug-containing granules), wet granulation granules (drug-free granules) and magnesium stearate into the mixer, set the mixing frequency to 20 Hz, and mix for 10 minutes to obtain the intermediate; 4) Tableting: Calculate the standard tablet weight based on the intermediate content, and control the tablet weight difference within ±3% for tableting; 5) Drying: Dry the plain tablets in a vacuum drying oven at 40°C for 16 hours. Example 4
[0031] Fluidized bed granulation and wet granulation step-by-step granulation process 2 (best embodiment) The prescription composition is the same as that of Example 1.
[0032] The preparation method comprises: 1) Fluidized bed granulation (drug-containing granules) ① Weighing: Accurately weigh the raw and auxiliary materials in the prescription and set aside; ② Preparation of adhesive: accurately weigh 3 / 4 of the prescription amount of purified water in a beaker, add the prescription amount of fumaric acid while stirring until completely dissolved, then add sodium citrate and dissolve completely, and finally stir and add 3 / 4 of the prescription amount of adhesive until completely dissolved to obtain a first adhesive solution; ③ Premixing: The prescribed amount of active ingredient mesartan potassium and filler mannitol are co-processed in a jet mill; the crushing pressure is 0.1~0.3MPa. The setting of 0.1~0.3MPa crushing pressure can reduce the adsorption and agglomeration of raw materials and make the raw materials and soluble excipients fully mixed.
[0033] ④ Add the mixture of active ingredient mesartan potassium and filler mannitol into the fluidized bed granulator, set the inlet air temperature to 55-65°C, the material temperature to 25-35°C, the air volume to 40-70m³ / h, add the first binder solution by atomization spraying, control the peristaltic pump liquid addition speed to 30-50rpm, the atomization pressure to 3-5bar, the material temperature to 25-35°C, perform fluidized bed granulation and drying, wait for the first binder solution to be sprayed, start sampling for moisture control 5 minutes later, stop drying when the moisture is <2%, and discharge the material; ⑤ Dry granulation: the granules are passed through a 1.0 mm sieve, the granulation machine frequency is controlled to 30 Hz, and the granules are weighed; 2) Wet granulation (without drug particles) ① Preparation of adhesive: accurately weigh 1 / 4 of the prescribed amount of purified water in a beaker, add 1 / 4 of the prescribed amount of adhesive while stirring until completely dissolved, to obtain a second adhesive solution; ② Premixing: Place the filler microcrystalline cellulose and the disintegrant cross-linked carboxymethyl cellulose sodium in a wet mixing granulator, set the stirring speed to 200 rpm and the cutting speed to 1000 rpm, and mix for 10 minutes; ③ Wet granulation: set the stirring speed to 200 rpm and the cutting speed to 1500 rpm, pump the second binder solution into the wet mixing granulator for granulation, control the binder to be added within 5 minutes, and stop the machine to discharge the material; ④ Wet granulation: soft materials pass through a 6*6mm aperture screen and the granulation machine frequency is controlled at 30Hz for granulation; ⑤ Drying: Set the inlet air temperature to 50~60℃, the material temperature to 30~40℃, and the air volume to 40~60m³ / h to dry the material. After drying for 10 minutes, take a sample to control the moisture content. If the moisture content is <2.0%, stop drying and discharge the material. ⑥ Dry granulation: the granules are passed through a 1.0 mm sieve, the granulation machine frequency is controlled to 30 Hz, and the granules are weighed; 3) Total mixing: Add the fluidized bed granulation granules (drug-containing granules), wet granulation granules (drug-free granules) and lubricant magnesium stearate into the mixer, set the mixing frequency to 20 Hz, and mix for 10 minutes to obtain the intermediate; 4) Tableting: Calculate the standard tablet weight based on the intermediate content, and control the tablet weight difference within ±3% for tableting; 5) Drying: Dry the plain tablets in a vacuum drying oven at 40°C for 16 hours.
[0034] Results Discussion and Analysis
[0035] The above data show that: when wet granulation is used alone, the material is easy to agglomerate, the particles are uneven, there are more large particles and fine powder, resulting in general fluidity; when fluidized bed granulation is used alone, there are more fine powder, smaller bulk density, and poor fluidity; Example 3 and Example 4 use fluidized bed and wet granulation in separate steps, the particles are uniform, the bulk density is moderate, and they have good fluidity and compressibility.
[0036] The reference preparation and the tablets of Examples 1 to 4 were tested for related substances using HPLC, and the results were as follows:
[0037] Evaluation of melted song: The dissolution curve was investigated in 0.5% sodium dodecyl sulfate pH 4.5 acetate buffer (37°C, rotation speed 50 rpm, medium 900 ml), and the results are as follows:
[0038] The above data show that: Example 1 adopts wet granulation, the raw material dissolution is less, which is different from the reference preparation. At the same time, due to the high water content of the material during the wet granulation process and the long-term contact with the raw material, the degradation product of the raw material drug, azilsartan, is larger; Example 2 adopts fluidized bed granulation, the raw material dissolves faster, and the dissolution amount is also increased, but the final dissolution platform is more than 10% lower than the reference preparation. Fluidized bed granulation can dry the particles in time to reduce the degradation of the raw material drug. The related substances of the sample in Example 2 are better than those in Example 1 and are similar to the reference preparation; Example 3 crushes the raw materials and adopts a step-by-step granulation process. The dissolution platform is further improved, but due to the hydrophobicity of the raw material itself, the early dissolution period (5-10min) is significantly different from the reference preparation. Step-by-step granulation is adopted to shorten the contact time between the raw material and the granulation liquid, further reducing the degradation of the raw material. The related substances of the sample in Example 3 are better than those of the reference preparation. In Example 4, on the basis of Example 3, the raw material is co-treated with mannitol to make the mixing more sufficient, so that the dissolution medium is easier to enter the interior of the granules and fully contact with the raw material. While ensuring the level of related substances, the dissolution platform is close to that of the reference preparation, and the dissolution curve is more similar to that of the reference preparation.
Claims
1. A tablet containing mesartan potassium, characterized in that: The composition is prepared by using the following components in parts by weight: 85-86 parts of asartan potassium, 220-240 parts of filler, 2-8 parts of pH adjuster, 8-12 parts of binder, 26-29 parts of disintegrant, and 3-4 parts of lubricant.
2. The tablet containing mesartan potassium according to claim 1, characterized in that: The filler is one or more of mannitol, lactose, and microcrystalline cellulose; the pH adjuster is one or more of fumaric acid, citric acid, and sodium citrate; the binder is one or more of hydroxypropyl cellulose, hydroxypropyl methylcellulose, and hydroxyethyl cellulose; the disintegrant is one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, and sodium starch glycolate; and the lubricant is one or more of magnesium stearate, stearic acid, and sodium stearyl fumarate.
3. The method for preparing a tablet containing asartan potassium according to claim 1, characterized in that: The following steps are involved: Add a pH adjuster to water and stir to dissolve completely, then stir and add a portion of the prescribed amount of binder until it is completely dissolved to obtain a first binder solution; co-process mesartan potassium and a filler in a jet mill, add the mixture to a fluidized bed granulator, add the first binder solution by atomizing spray, perform fluidized bed granulation and drying, and obtain fluidized bed granulation particles after dry granulation; Add the remaining amount of binder in the prescription into the water while stirring until it is completely dissolved to obtain a second binder solution; place the filler and the disintegrant in a wet mixing granulator for premixing, increase the cutting speed after the premixing is complete, pump the second binder solution into the wet mixing granulator for granulation, and perform wet granulation, and perform dry granulation after drying to obtain wet granulated granules; The fluidized bed granulation granules, the wet granulation granules and the lubricant are mixed to obtain an intermediate, and the intermediate is tableted to obtain a tablet containing mesartan potassium.
4. The method for preparing a tablet containing asartan potassium according to claim 3, characterized in that: The ratio of the adhesives used in the first adhesive solution and the second adhesive solution is 3:1-2.
5. The method for preparing a tablet containing asartan potassium according to claim 3, characterized in that: Add mesartan potassium and filler into the fluidized bed granulator, with the inlet air temperature of 55~65℃, the material temperature of 25~35℃, and the air volume of 40~70m³ / h.
6. The method for preparing a tablet containing asartan potassium according to claim 3, characterized in that: The first binder solution is added by atomizing spray, the peristaltic pump adding speed is controlled at 30-50 rpm, the atomizing pressure is controlled at 3-5 bar, and fluidized bed granulation and drying are performed.
7. The method for preparing a tablet containing asartan potassium according to claim 3, characterized in that: The dry granulation step comprises: passing the dried granules through a 1.0±0.1 mm aperture sieve, and controlling the granulation machine frequency to 30±2 Hz for granulation.
8. The method for preparing a tablet containing asartan potassium according to claim 3, characterized in that: The method of placing the filler and the disintegrant in a wet mixing granulator for premixing, increasing the cutting speed after the premixing is complete, and pumping the second binder solution into the wet mixing granulator for granulation comprises: placing the filler and the disintegrant in a wet mixing granulator for premixing, wherein the stirring speed of the premixing is 200±10rpm, the cutting speed is 1000±100rpm, and the mixing time is 10±2min; setting the stirring speed to 200rpm, the cutting speed to 1500rpm, and pumping the second binder solution into the wet mixing granulator for granulation.
9. The method for preparing a tablet containing asartan potassium according to claim 3, characterized in that: The mixing frequency of the total mixing is 20±2 Hz, and the mixing time is 10±2 min.
10. The method for preparing a tablet containing asartan potassium according to claim 3, characterized in that: The drying of the intermediate tablets specifically comprises: drying the intermediate in a reduced pressure drying oven at 40±2° C. for 16±2 h.
Citation Information
Cited By
Stable Milsartan potassium tablet and preparation method thereof
CN119792218A
A stable potassium moiety tablet of meloxicam and a method for preparing the same
CN119792218B
